Key result
AdVammin gene therapy increases stress LVEF vs control in ischemic porcine hearts, inducing robust angiogenesis.
Why the study?
To investigate whether VEGFR-2 selective adenoviral Vammin gene therapy could induce angiogenesis and increase perfusion in healthy porcine myocardium and improve cardiac function in a chronically ischemic model.
Does low dose AdVammin gene transfer induce angiogenesis and improve function in ischemic porcine hearts?
Does low dose AdVammin gene transfer induce angiogenesis and improve function in ischemic porcine hearts?
Absolute Event Rate: 7.75% vs 2.25%
p-value: p=0.045
Low dose AdVammin gene therapy induces myocardial angiogenesis and improves ejection fraction in ischemic porcine hearts, but its therapeutic potential is limited by increased tissue permeability and pericardial effusion.
Pericardial effusion limits translation; hypothesis-generating for AdVammin angiogenesis in ischemic cardiomyopathy.
This preliminary study investigated if VEGFR-2 selective adenoviral Vammin (AdVammin) gene therapy could induce angiogenesis and increase perfusion in the healthy porcine myocardium. Also, we determined using a clinically relevant large animal model if AdVammin gene therapy could improve the function of a chronically ischemic heart. Low doses of AdVammin (dose range 2 × 10 9 –2 × 10 10 vp) gene transfers were performed into the porcine myocardium using an endovascular injection catheter. AdCMV was used as a control. The porcine model of chronic myocardial ischemia was used in the ischemic studies. The AdVammin enlarged the mean capillary area and stimulated pericyte coverage in the target area 6 days after the gene transfers. Using positron emission tomography 15 O-radiowater imaging, we demonstrated that AdVammin gene therapy increased perfusion in healthy myocardium at rest. AdVammin treatment also increased ejection fraction at stress in the ischemic heart, as detected using left ventricular cine angiography. In addition, we demonstrated successful in vivo imaging of enhanced angiogenesis using [ 68 Ga]NODAGA-RGD peptide. However, AdVammin also increased tissue permeability and was associated with significant pericardial fluid accumulation, limiting AdVammin’s therapeutic potential and emphasizing the importance of correct dosage.
No takes yet. Share an insight, caveat, or question.
Järveläinen et al. (2024) studied Myocardial ischemia (n=37). Adenoviral Vammin (AdVammin) vs. AdCMV (empty adenovirus) was evaluated on Mean change in left ventricular ejection fraction from baseline to 6 days during stress (p=0.045). AdVammin gene therapy significantly increased left ventricular ejection fraction during stress compared to control in ischemic porcine hearts, while also inducing robust myocardial angiogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: